Literature DB >> 16046525

CD94 1A transcripts characterize lymphoblastic lymphoma/leukemia of immature natural killer cell origin with distinct clinical features.

Chung-Wu Lin1, Ting-Yun Liu, Shee-Uan Chen, Kun-Teng Wang, L Jeffrey Medeiros, Su-Ming Hsu.   

Abstract

Most lymphoblastic lymphomas (LBLs) are regarded as neoplasms of immature T cells because they express cytoplasmic CD3 and frequently carry T-cell receptor (TCR) gene rearrangements. Immature natural killer (NK) and T cells, however, have a common bipotent T/NK-cell precursor in the thymus, and NK cells also express cytoplasmic CD3. Thus, some LBLs could arise from immature NK cells. Mature NK cells express 2 CD94 transcripts: 1A, induced by interleukin 15 (IL-15), and 1B constitutively. Because immature NK cells require IL-15 for development, CD94 1A transcripts could be a marker of NK-LBL. To test this hypothesis, we used laser capture microdissection to isolate IL-15 receptor alpha(+) lymphoid cells from the thymus and showed that these cells contained CD94 1A transcripts. We then assessed for CD94 transcripts in 21 cases of LBL that were cytoplasmic CD3(+), nuclear terminal deoxynucleotidyl transferase positive (TdT(+)), and CD56(-), consistent with either the T-cell or NK-cell lineage. We found that 7 LBLs expressed CD94 1A transcripts without TCR gene rearrangements, suggesting NK-cell lineage. Patients with NK-LBL were younger than patients with T-LBL (15 years versus 33 years; P = .11) and had a better 2-year survival (100% versus 27%; P < .01). These results improve the current classification of LBL and contribute to our understanding of NK-cell differentiation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16046525     DOI: 10.1182/blood-2005-02-0519

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  7 in total

Review 1.  The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance.

Authors:  Francisco Borrego; Madhan Masilamani; Alina I Marusina; Xiaobin Tang; John E Coligan
Journal:  Immunol Res       Date:  2006       Impact factor: 2.829

2.  CD56 expression in T-cell acute lymphoblastic leukemia is associated with non-thymic phenotype and resistance to induction therapy but no inferior survival after risk-adapted therapy.

Authors:  Lars Fischer; Nicola Gökbuget; Stefan Schwartz; Thomas Burmeister; Harald Rieder; Monika Brüggemann; Dieter Hoelzer; Eckhard Thiel
Journal:  Haematologica       Date:  2008-12-23       Impact factor: 9.941

Review 3.  Updates in the Pathology of Precursor Lymphoid Neoplasms in the Revised Fourth Edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues.

Authors:  Christopher Wenzinger; Eli Williams; Alejandro A Gru
Journal:  Curr Hematol Malig Rep       Date:  2018-08       Impact factor: 3.952

4.  Pediatric myeloid/NK cell precursor lymphoma/leukemia expressing T/NK immunophenotype markers.

Authors:  Yoshiko Hashii; Tokuko Okuda; Hideaki Ohta; Keiichi Ozono; Junichi Hara
Journal:  Int J Hematol       Date:  2010-02-10       Impact factor: 2.490

Review 5.  Natural killer cell neoplasm: biology and pathology.

Authors:  Maria Francisca Ham; Young-Hyeh Ko
Journal:  Int J Hematol       Date:  2010-12-07       Impact factor: 2.490

Review 6.  Scientific considerations for evaluating cancer bioassays conducted by the Ramazzini Institute.

Authors:  Jeffrey S Gift; Jane C Caldwell; Jennifer Jinot; Marina V Evans; Ila Cote; John J Vandenberg
Journal:  Environ Health Perspect       Date:  2013-09-17       Impact factor: 9.031

7.  T-lymphoblastic lymphoma/leukemia without clonal TCR gene rearrangements: case report and literature review.

Authors:  Jiuju Wang; Shanshan Jiang; Qiaojiajie Zhao; Xucang Wei; Wensheng Li
Journal:  Transl Cancer Res       Date:  2021-03       Impact factor: 1.241

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.